A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer

Given the promising activity and tolerability of FOLFIRINOX as a second-line treatment for advanced biliary tract cancer (BTC), it can be an attractive first-line treatment option as well. This is a single-arm, open-label, multicenter phase II study to evaluate the safety and efficacy of FOLFIRINOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahara, Naminatsu, Nakai, Yousuke, Isayama, Hiroyuki, Sasaki, Takashi, Morine, Yuji, Watanabe, Kazuo, Ueno, Makoto, Ioka, Tatsuya, Kanai, Masashi, Kondo, Shunsuke, Okano, Naohiro, Koike, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718456/
https://www.ncbi.nlm.nih.gov/pubmed/36459291
http://dx.doi.org/10.1007/s10637-022-01322-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718456/
https://www.ncbi.nlm.nih.gov/pubmed/36459291
http://dx.doi.org/10.1007/s10637-022-01322-7

Ejemplares similares